Advanced pancreatic ductal adenocarcinoma (PDAC) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality, accounting for up to 4% of cancer-related deaths worldwide. Of concern, despite treatment, the mortality rates remain high and essentially unchanged over the last two decades. Furthermore, even in adjuvant therapy, 5-year survival rates remain poor at only 25%, while for metastatic disease, it is 1%. Such poor statistics are undoubtedly compounded by the fact that current backbones to treatment, fluorouracil or gemcitabine, have remained unchanged over the last 10-20 years and continue to form the basis for new combinations approaches. Consequently, there is an ongoing need for the development of improved diagnostic techniques, treatment options, and surveillance markers to enhance the outcomes of this devastating disease.

 

Pancreaticoduodenectomy is the most common surgery for pancreatic head carcinomas. Incidence of benign disease at pancreatiduodenectomy ranges from approximately 6% to 10%.

 

The competitive landscape of Advanced pancreatic ductal adenocarcinoma (PDAC) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Advanced pancreatic ductal adenocarcinoma (PDAC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Advanced pancreatic ductal adenocarcinoma (PDAC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Advanced pancreatic ductal adenocarcinoma (PDAC) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Nivolumab         Bristol-Myers Squibb      Phase 2

2          Eryaspase        ERYtech Pharma          Phase 1

3          Gemcitabine     Agenus Inc.      Phase 2

4          FOLFIRI           OSE Immunotherapeutics          Phase 2

5          CEND-1            Qilu Pharmaceutical Co., Ltd.     Phase 2

6          KN046  Alphamab Oncology      Phase 2

7          Oxaliplatin         TTY Biopharm   Phase 2

8          siG12D-LODER Silenseed Ltd    Phase 2

9          CEND-1            Cend Therapeutics Inc.  Phase 2

10        Romidepsin       AstraZeneca     Phase 2

Continued